HDT bio's Rapid-Response Roadmap for RNA vaccines (R 4 ) project granted a five-year subaward for $2M per year SEATTLE , Sept. 17, 2024 /PRNewswire/ -- HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud to announce its pivotal role in PROVIDENT (Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics Against Diverse Emerging Infectious Threats), a national consortium led by Albert Einstein College of Medicine and funded by the National Institute of Allergy and Infectious Diseases (NIAID) as part of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network.
HDT Bio will focus on developing "road maps" for the rapid creation of RNA vaccines against pathogens with pandemic potential, harnessing the company's proprietary AMPLIFYTM self-amplifying replicon RNA (repRNA) platform and LIONTM nanoparticle delivery system. The combination of these two technologies offers increased vaccine potency, durability, and stability, while simplifying production—critical features for addressing emerging infectious threats quickly and effectively. "We are excited to contribute our expertise in RNA vaccine technologies to the PROVIDENT consortium," said Steve Reed , Ph.
D., Chief Executive Officer of HDT Bio. "Our AMPLIFYTM and LIONTM platforms have demonstrated their ability to rapidly generate potent, durable immune responses with a favorable safety profile.
Th.